Peter Kufer

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Hermann Einsele, Carsten Reinhardt, Thomas Burmeister, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct1

Iduna Fichtner, P. Kufer, I. Fichtner, 2003, The Journal of Immunology.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Andreas Wolf, Dirk Nagorsen, Monika Brüggemann, 2012, Blood.